Stockreport

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Inc.  (LTRN) 
PDF Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.Fast Track Designation for LP [Read more]